FOUND: Fda skeptical of experimental als treatment pushed by patient advocates - You Need To See This

The Food and Drug Administration meets this week to consider approval of an experimental treatment for Lou Gehrig’s disease, the culmination of a yearslong lobbying effort by patients with the fatal neurodegenerative disease.

Those advocates still face one giant hurdle: FDA regulators say the treatment hasn't been shown to work.